{"id":42608,"date":"2026-01-12T22:27:00","date_gmt":"2026-01-12T22:27:00","guid":{"rendered":"http:\/\/www.prnasia.com\/story\/archive\/4861479_AE61479_0"},"modified":"2026-01-12T22:27:00","modified_gmt":"2026-01-12T22:27:00","slug":"alamar-biosciences-announces-launch-of-nulisaqpcr-ad-5-plex-assay-advancing-blood-based-biomarker-detection-in-alzheimers-disease-research","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=42608","title":{"rendered":"Alamar Biosciences Announces Launch of NULISAqpcr\u2122 AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer&#8217;s Disease Research"},"content":{"rendered":"<div id=\"dvContent\" readability=\"104.05829596413\">\n<p><span class=\"legendSpanClass\">FREMONT, Calif.<\/span>, <span class=\"legendSpanClass\">Jan. 13, 2026<\/span> \/PRNewswire\/ &#8212; Alamar Biosciences, Inc. (&#8220;Alamar&#8221;), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of its Research Use Only (RUO) NULISAqpcr\u2122 AD 5-plex Assay. This innovative solution enables simultaneous quantitative measurement of five critical blood-based biomarkers relevant to the Alzheimer&#8217;s Association recommended guidelines: brain-derived phosphorylated tau 217 (BD-pTau217), neurofilament light chain (NfL), amyloid-beta 42 (A\u03b242), glial fibrillary acidic protein (GFAP), and APOE4 (carrier status), all from a single blood or plasma sample.<\/p>\n<div id=\"prni_dvprnejpgd03fleft\" dir=\"ltr\"> <a href=\"https:\/\/mma.prnasia.com\/media2\/2859769\/Alamar_NULISAqpcr_AD_5_plex.jpg?p=medium600\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" id=\"prnejpgd03fleft\" title=\"NULISAqpcr AD 5-plex Assay includes BD-pTau217, GFAP, NfL, AB42 and APOE4.\" src=\"https:\/\/mma.prnasia.com\/media2\/2859769\/Alamar_NULISAqpcr_AD_5_plex.jpg?p=medium600\" alt=\"NULISAqpcr AD 5-plex Assay includes BD-pTau217, GFAP, NfL, AB42 and APOE4.\" align=\"middle\"><\/a> <br \/><span>NULISAqpcr AD 5-plex Assay includes BD-pTau217, GFAP, NfL, AB42 and APOE4.<\/span> <\/div>\n<p>The NULISAqpcr AD 5-plex Assay consolidates key biomarkers into a single multiplexed format, delivering unmatched sensitivity, specificity, and ease of use. By incorporating BD-pTau217, A\u03b242, NfL, and GFAP, the assay enables robust monitoring of amyloid and tau pathology, neurodegeneration, and inflammation, while accurately determining APOE4 carrier status\u2014the strongest genetic risk factor for Alzheimer&#8217;s disease. Together, these capabilities create a powerful tool for both translational and clinical research, and its relevance extends beyond Alzheimer&#8217;s disease to other neurodegenerative and cognitive disorders.<\/p>\n<p>&#8220;The launch of the NULISAqpcr AD 5-plex Assay marks a significant milestone in our efforts to deliver precision proteomics solutions for neurodegenerative disease,&#8221; said Dr. Yuling Luo, founder, chairman and chief executive officer of Alamar. &#8220;By combining these critical protein targets into a single assay with a streamlined workflow, we are empowering the neuroscience community to advance screening, early detection and precision diagnoses for Alzheimer&#8217;s disease.&#8221;<\/p>\n<p>&#8220;Blood-based biomarkers are redefining Alzheimer&#8217;s research, providing an accurate, cheaper and more accessible means of establishing early diagnosis and aiding determination of eligibility for therapies,&#8221; said Dr. Steven Williams, chief scientific officer of Alamar. &#8220;Traditional single-plex assays can measure these biomarkers individually, but require multiple tests to provide a comprehensive view of the disease. With NULISA\u2122 it is now possible to measure multiple Alzheimer&#8217;s-related proteins in blood, each offering unique insights into the underlying pathophysiology.&#8221;<\/p>\n<p>Alamar is dedicated to collaborating with researchers, clinicians, and industry partners to unlock precision proteomics and improve outcomes for patients affected by Alzheimer&#8217;s disease and other neurodegenerative conditions. The NULISAqpcr AD 5-plex Assay is available today as a service through our Technology Access Program.<\/p>\n<p>For more information about the NULISAqpcr AD 5-plex Assay and Alamar&#8217;s full portfolio of precision proteomic solutions, visit <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4594086-1&amp;h=2684776203&amp;u=https%3A%2F%2Falamarbio.com%2Fnulisaqpcr-ad-5-plex-assay%2F%3Futm_source%3Dpr&amp;a=www.alamarbio.com\" target=\"_blank\" rel=\"nofollow noopener\">www.alamarbio.com<\/a>.<\/p>\n<p><b>About&nbsp;Alamar Biosciences, Inc.<\/b><\/p>\n<p>Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA\u2122 technology and the ARGO\u2122 HT System, Alamar&#8217;s platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit&nbsp;<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4594086-1&amp;h=2869490671&amp;u=https%3A%2F%2Fwww.alamarbio.com%2F%3Futm_source%3DPR&amp;a=alamarbio.com\" target=\"_blank\" rel=\"nofollow noopener\">alamarbio.com<\/a>.&nbsp;<\/p>\n<div id=\"prni_dvprnejpgff21left\" dir=\"ltr\"> <a href=\"https:\/\/mma.prnasia.com\/media2\/1810182\/Alamar_Logo_WhiteOutline_RGB_4x1_Logo_V1.jpg?p=medium600\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" id=\"prnejpgff21left\" title src=\"https:\/\/mma.prnasia.com\/media2\/1810182\/Alamar_Logo_WhiteOutline_RGB_4x1_Logo_V1.jpg?p=medium600\" alt align=\"middle\"><\/a> <br \/><span><\/span> <\/div>\n<\/p><\/div>\n<p>Source: Alamar Biosciences, Inc.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FREMONT, Calif., Jan. 13, 2026 \/PRNewswire\/ &#8212; Alamar Biosciences, Inc. (&#8220;Alamar&#8221;), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of its Research Use Only (RUO) NULISAqpcr\u2122 AD 5-plex Assay. This innovative solution enables simultaneous quantitative measurement of five critical blood-based biomarkers relevant to the [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-42608","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alamar Biosciences Announces Launch of NULISAqpcr\u2122 AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer&#039;s Disease Research - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=42608\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alamar Biosciences Announces Launch of NULISAqpcr\u2122 AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer&#039;s Disease Research - My Blog\" \/>\n<meta property=\"og:description\" content=\"FREMONT, Calif., Jan. 13, 2026 \/PRNewswire\/ &#8212; Alamar Biosciences, Inc. (&#8220;Alamar&#8221;), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of its Research Use Only (RUO) NULISAqpcr\u2122 AD 5-plex Assay. This innovative solution enables simultaneous quantitative measurement of five critical blood-based biomarkers relevant to the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=42608\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T22:27:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/2859769\/Alamar_NULISAqpcr_AD_5_plex.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=42608#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=42608\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Alamar Biosciences Announces Launch of NULISAqpcr\u2122 AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer&#8217;s Disease Research\",\"datePublished\":\"2026-01-12T22:27:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=42608\"},\"wordCount\":468,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=42608#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2859769\\\/Alamar_NULISAqpcr_AD_5_plex.jpg?p=medium600\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=42608\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=42608\",\"name\":\"Alamar Biosciences Announces Launch of NULISAqpcr\u2122 AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=42608#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=42608#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2859769\\\/Alamar_NULISAqpcr_AD_5_plex.jpg?p=medium600\",\"datePublished\":\"2026-01-12T22:27:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=42608#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=42608\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=42608#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2859769\\\/Alamar_NULISAqpcr_AD_5_plex.jpg?p=medium600\",\"contentUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2859769\\\/Alamar_NULISAqpcr_AD_5_plex.jpg?p=medium600\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=42608#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alamar Biosciences Announces Launch of NULISAqpcr\u2122 AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer&#8217;s Disease Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alamar Biosciences Announces Launch of NULISAqpcr\u2122 AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=42608","og_locale":"en_US","og_type":"article","og_title":"Alamar Biosciences Announces Launch of NULISAqpcr\u2122 AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research - My Blog","og_description":"FREMONT, Calif., Jan. 13, 2026 \/PRNewswire\/ &#8212; Alamar Biosciences, Inc. (&#8220;Alamar&#8221;), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of its Research Use Only (RUO) NULISAqpcr\u2122 AD 5-plex Assay. This innovative solution enables simultaneous quantitative measurement of five critical blood-based biomarkers relevant to the [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=42608","og_site_name":"My Blog","article_published_time":"2026-01-12T22:27:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/2859769\/Alamar_NULISAqpcr_AD_5_plex.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=42608#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=42608"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Alamar Biosciences Announces Launch of NULISAqpcr\u2122 AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer&#8217;s Disease Research","datePublished":"2026-01-12T22:27:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=42608"},"wordCount":468,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=42608#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/2859769\/Alamar_NULISAqpcr_AD_5_plex.jpg?p=medium600","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=42608","url":"https:\/\/transmediavictoria.net.au\/?p=42608","name":"Alamar Biosciences Announces Launch of NULISAqpcr\u2122 AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=42608#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=42608#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/2859769\/Alamar_NULISAqpcr_AD_5_plex.jpg?p=medium600","datePublished":"2026-01-12T22:27:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=42608#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=42608"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=42608#primaryimage","url":"https:\/\/mma.prnasia.com\/media2\/2859769\/Alamar_NULISAqpcr_AD_5_plex.jpg?p=medium600","contentUrl":"https:\/\/mma.prnasia.com\/media2\/2859769\/Alamar_NULISAqpcr_AD_5_plex.jpg?p=medium600"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=42608#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Alamar Biosciences Announces Launch of NULISAqpcr\u2122 AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer&#8217;s Disease Research"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/42608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42608"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/42608\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}